

4 December 2024

Hall A - Matrah	Hall B - Salalah	Hall C - Nizwa	Hall D - Sur
7:30 9:00 Registration			
9:15 9:30 Welcome Remarks			
9:30 11:00 Plenary Session: The Atherogenic Environment Chairpersons: Lale Tokgozoglu, Turkey Dirk Blom, South Africa			
9:30 10:00 Bone Marrow Inflammation and Atherosclerosis Peter Libby, USA			
10:00 10:30 How Modeling of Cardiovascular Benefits May Aid Implementation of Public Health Policies Kausik Ray, UK			
10:30 11:00 Emerging Topics in Women's Cardiovascular Health Samia Mora, USA			
11:00 - 11:30 Coffee Break / Exhibition / Poster Viewing			
11:30 12:30 Parallel Session: Emerging New Therapies and Gene Therapies in Atherosclerotic Cardiovascular Diseases Chairpersons: Mariko Harada-Shiba, Japan Marianne Abifadel, Lebanon Kadhim Sulaiman, Oman	11:30 12:30 Parallel Session: Latest in Clinical Trials: From Design to Outcomes Chairpersons: Gerald Watts, Australia Mustafa Al Hinai, Oman Yufen Cheng, China	11:30 12:30 Parallel Session: Precision Medicine in Atherosclerotic Disease: Challenges and Opportunities Chairpersons: Abdullah Al Maniri, Oman Amirhossein Sahebkar, Iran Mirvat Alasnag, Saudi Arabia	11:30 12:30 Parallel Session: Health Economics and Policy Considerations Related to Cardiometabolic Diseases Chairpersons: Khurram Nasir, USA Xin Chen, China Wael AlMahmeed, UAE
11:30 11:50 Advances in lipid lowering therapies for homozygous familial hypercholesterolaemia Frederick Raal, South Africa	11:30 11:45 The Impact of Triglyceride Levels on Achieving Non-HDL-C Targets in Patients with Very High Cardiovascular Risk and Controlled LDL-C: Data from Gulf CALLS Study Manal Al Kindi, Oman	11:30 11:50 Metabolomics, inflammation, and precision medicine Samia Mora, USA	11:30 11:50 Non-Communicable Diseases: Policy Implications and Insights from Oman Shadha S. Al-Raisi, Oman
11:50- 12:10 Novel Approaches To Atherosclerosis What Is Now And What Is Coming Lipoprotein A, Oral Pcsk9, Cetp, Inflammation, Gene Editing Hani Sabbour, UAE		11:50 12:10 Optimizing macrovascular and microvascular risk reduction in patients with diabetes and dyslipidemia Alberto Zambon, Italy	11:50 12:10 NCD investment case Rasha Alfawaz, Saudi Arabia

12:10 12:20	Results from the largest meta-GWAS performed on PCSK9 concentrations Azin Kheirkhah, Austria	11:45 12:05	Gulf Action registry: Final Results Khalid Al Habib, Saudi Arabia	12:10 12:20	Atherosclerotic Cardiovascular Disease Risk Prediction: The United States Pooling Project Ernst Schaefer, USA	12:10 12:20	Socioeconomic inequalities and dyslipidemia in Ravansar cohort study Neda Izadi, Australia
12:20 12:30	Epigenetic modulation of Endothelial-to-Mesenchymal Transition in diabetes associated atherosclerosis Misbah Aziz, Australia	12:05 12:15	Relative atherogenicity of apoB-containing lipoproteins Jan Boren, Sweden	12:20 12:30	Oman Cardiovascular Initiative: Precision Medicine for Risk Prediction and Cholesterol Lowering Khalid Al Rasadi, Oman	12:20 12:30	Lp(a) Taskforce - An Innovative, Multistakeholder Approach to Cardiovascular Health Tobias Silberzahn, Germany
12:30 13:30	Sponsored Symposium - R3i Session Title: Micro-vascular Complications in Diabetic Patients Chairpersons: Peter Libby, USA Khalid Al Rasadi, Oman Diabetic Nephropathy Burden and Management in the MENA Region Nasreen Al-Sayed, Bahrain A Novel Therapeutic Approach for Diabetic Retinopathy -Exploring New Molecular Targets Yohei Tomita Pemafibrate to Treat and Prevent Diabetic Foot Ulcers: A Major Unmet Clinical Need Requiring Formal Evaluation Paul Ridker, USA	12:30 13:00	Sponsored Symposium - AstraZeneca Beyond Dyslipidemia: Identifying Rare Diseases through Atherogenic Biomarkers Nadia Al Hashmi, Oman	12:30 13:30	Sponsored Symposium: Novartis Pharma Service AG Session Title: Contemporary Approaches to Addressing Cardiovascular Risk in Patients with ASCVD Chairperson: Khalid Alwaili, Oman Shaping ASCVD Care: Cutting-Edge Treatment Approaches Raul Santos, Brazil Uncovering a Hidden Player in ASCVD: Lp(a) Hani Sabbour, UAE	12:30 13:00	Sponsored Symposium: Business International Group LLC (BIG) Genomics precision medicine and cardiovascular disease Walid Qoronf, USA
						13:00 13:15	Sponsored Symposium: Kaneka Medical Selective apheresis with dextrane sulphate in lipoproteins disorders Andrea Petta, Italy

13:30 - 14:30 Coffee Break / Exhibition / Poster Viewing

14:30 16:00	Plenary Sessions - Pinpointing Atherosclerosis Chairpersons: Samia Mora, USA Manal Al Kindi, Oman Michal Vrablik, Czech Republic						
14:30 15:00	Precision Medicine in Atherosclerotic Disease: Challenges and Opportunities Ashna Nastar, Singapore						
15:00 15:30	Recent Advances in Imaging in Atherosclerotic Cardiovascular Disease Khurram Nasir, USA						
15:30 16:00	Digital Health and Artificial Intelligence for Personalized Prevention of Atherosclerosis and Associated Cardiometabolic Diseases Olga Demler, Switzerland						

16:00 - 17:00 Coffee Break / Exhibition

17:00 - 18:00 Opening Ceremony

18:00 - 19:00 Opening Reception

5 December 2024 - Program

Hall A - Matrah	Hall B - Salalah	Hall C - Nizwa	Hall D - Sur
07:30 - Onwards Registration			
8:15 - 9:00 Gotto Award Lecture: Valentin Fuster, USA			
9:00 - 10:30 Plenary Sessions - Advances in Lipoproteins Chairpersons: Ioanna Gouni-Berthold, Germany Fahad Al Zadjali, Oman			
9:00 - 9:30 Lipoprotein(a) and Cardiovascular Disease Borge G Nordestgaard, Denmark			
9:30 - 10:00 What to target - Triglycerides, HDL or remnant cholesterol? Kerry-Anne Rye, Australia			
10:00 - 10:30 Novel Therapies for Lowering LDL & ApoB Raul Santos, Brazil			
10:30 - 11:00 Coffee Break / Exhibition / Poster Viewing			
11:00 - 12:30 Parallel Session: Lipoprotein(a), HDL and apoB in Atherosclerosis: Pathophysiology, Diagnosis, and Treatment Chairpersons: Said Al Hinai, Oman Ioanna Gouni-Berthold, Germany Mohammed Ammar, Egypt	11:00 - 12:30 Parallel Session: Novel Therapies for Obesity and Cardiometabolic Diseases Chairpersons: Ibrahim Al Rashdi, Oman Ada Cuevas, Chile	11:00 - 12:30 Parallel Session: Advances in Familial Hypercholesterolemia Chairpersons: Fahad Al-Nouri, Saudi Arabia Dirk Blom, South Africa Carine Ayoub, Lebanon	11:00 - 12:30 Parallel Session: Women's Cardiovascular Health Issues Chairpersons: Christina Bursil, Australia Rahma Al Kindi, Oman Peter Libby, USA
11:00 - 11:20 Elucidate the complex metabolism of Lipoprotein (a) to design optimal Lp(a) lowering drugs. Gilles Lambert, France	11:00 - 11:20 Medications developed for type 2 diabetes Brian Tomlinson, China	11:00 - 11:20 Cardiovascular risk in FH: have it changed in the last decade Rodrigo Alonso, Chile	11:00 - 11:20 Women lipids and ASCVD. Lale Tokgozoglu, Turkey
11:20 - 11:40 RADICAL study: Real life results of Inclisiran Khalid Al Habib, Saudi Arabia	11:20 - 11:40 Beyond GLP-1 – What's next for obesity treatment? John Wilding, UK	11:20 - 11:40 Familial Hypercholesterolemia in Iran Nizal Sarrafzadegan, Iran	11:20 - 11:40 Breast arterial calcification and cardiovascular disease Jessica Peña, USA
11:40 - 12:00 Beyond LDL: The Obesity & measurable lipids Mirvat Alasnag, Saudi Arabia	11:40 - 11:50 Bempedoic Acid Reduces Cardiovascular Events: Systematic Review and Meta-Analysis Rahmeh Al-Asmar, Jordan	11:40 - 12:00 PCSK9: from gene discovery to new treatment in familial hypercholesterolemia Marianne Abifadel, Lebanon	11:40 - 12:00 Cardiac disease in Arabian women Juwaria Al Ali, UAE
12:00 - 12:10 Elevated Lipoprotein (a) and its phenotype characteristics in premature CAD Amani Al Khaifi, Oman	11:50 - 12:05 Bariatric Surgery and Cardiometabolic Health Amira Al-Kharusi, Oman	12:00 - 12:20 Familial hypercholesterolemia: Proper diagnosis and strict treatment can improve the prognosis Mariko Harada-Shiba, Japan	12:00 - 12:10 Meat intake, metabolomics, and cardiovascular disease risk in 27,154 women Shafqat Ahmad, Sweden
12:10 - 12:20 Familial hypercholesterolemia and hyperlipoproteinemia(a) in acute coronary syndrome patients Svetlana Bliznyuk, Moscow	12:05 - 12:20 Nutritional Interventions and Cardiometabolic health Ada Cuevas, Chile	12:20 - 12:30 Lomitapide Phase-3 study in pediatric homozygous familial hypercholesterolemia (HoFH): APH-19 Naji Kholoif, Saudi Arabia	12:10 - 12:20 Comparing the accuracy of ACC/AHA and WHO risk-models in ICS Zahra Teimouri-Jervekani, Iran
			12:20 - 12:30 Adherence to statins and MACE in patients with severe hypercholesterolemia Bariyat Tamaeva, Russia

12:20 12:30	ApoB-containing lipoprotein atherogenicity in Hypertriglyceridemia: Is it only Cholesterol? John Chapman, France	12:20 12:30	SCAP as a Potential Therapeutic Target for Colorectal Cancer Aisha Al-Naamani, Oman		
12:30 13:30	Sponsored Symposium - Kowa Session Title: Unravelling The Potential of SPPARMa with Appraisal of Cumulative Evidence Chairperson: Paul M. Ridker, USA Triglycerides as a Modifiable Risk Factor and Therapeutic Target for Cardiovascular Disease Satoshi Yasuda, Japan Lessons from the PROMINENT Trial and Future Perspectives Shizuya Yamashita, Japan	12:30 13:30	GCDC Symposium Session Title: Regional best practices in NCD prevention and control Chairperson: Rasha Alfawaz, Saudi Arabia The Health Support Cooperative Initiative Humoud Alzuabi, Kuwait The Public Health Authority's vision for a customized CVD risk assessment tool Marwa Alnaghmishi, Saudi Arabia	12:30 13:30	Sponsored Symposium - Chiesi Session Title: Bridging Borders in Homozygous Familial Hypercholesterolemia: Collaborative Insights from Europe and the Gulf to improve management Chairpersons: Marcello Arca, Italy Naji Kholaif, KSA
12:30 13:15				12:30 13:15	Sponsored Symposium - Merck Chairperson: Peter Libby, USA CV risk and disease burden in the Middle East: Where are we in 2024? Hani Sabbour, UAE Cumulative LDL burden – how to tackle it today and tomorrow? Sadberk Lale Tokgözoğlu, Turkey
13:30 - 14:30 Coffee Break / Exhibition / Poster Viewing					
14:30 16:00	Parallel Session: Triglyceride-rich Lipoproteins, ApoC-III, and Cardiovascular Disease: Implications for Prevention and Treatment Chairpersons: Shafqat Ahmad, Sweden Nasreen Al Sayed, Bahrain Manfredi Rizzo, Italy	14:30 16:00	Parallel Session: Late Breaking Session Chairpersons: Khamis Al-Hashmi, Oman Ashna Nastar, Singapore Lale Tokgozoglu, Turkey	14:30 16:00	Parallel Session: Diabetes and Atherosclerosis: Lifestyle Rather than Deathstyle Chairpersons: Banshi Saboo, India Amira Al-Kharusi, Oman Brian Tomlinson, China
14:30 14:50	Treatment of Hypertriglyceridemia for Cardiovascular Disease Prevention: Lessons from the PROMINENT Trial. Shizuya Yamashita, Japan	14:30 14:40	N-Glycosylation Profiles of Plasma Glycans and Future Cardiovascular Events Mohammed Ammar, Egypt	14:30 14:50	Lifestyle Medicine: An Evidence-Based Approach to Chronic Disease Management Saleh Alrajhi, Saudi Arabia
14:50 15:10	Expert Speaker - Current & Future Therapeutic Options for FCS Ioanna Gouni-Berthold, Germany	14:40 14:50	Mitochondrial transplantation induces cardioprotection in rats with coronary artery disease Reza Badalzadeh, Iran	14:50 15:10	An overview of the Ideal Weight Challenge: a school based intervention project in Oman Sulaiman Al Shereiqli, Oman
15:10 15:30	Postprandial metabolism of apoB-containing lipoproteins APOC3 loss-of-function or gain-of-function mutations Jan Boren, Sweden	14:50 15:00	Metabolomics-Based Lifestyle Score Captures Cardiometabolic Risk in Elderly Obesity Yifan Chen, China	15:10 15:30	Diabetes&Inflammation; The Journey from Theory to Practice Noha Amin, Egypt
15:30 15:40	Genetic Landscape of FCS and MCS in the United Kingdom Bilal Bashir, UK	15:00 15:10	Metabolic Health in Individuals with Different Self-efficacy in Healthy Behaviors Mahdieh Niknam, Iran	15:30 15:40	Improved Cardiometabolism in Arab Adolescents Post 12-month Lifestyle Modification Program Nasser Al-Daghri, Saudi Arabia
15:40 16:00	Apolipoprotein-E Concentrations Are Predictive Of Recurrent Strokes: The Sparcl Trial Gilles Lambert, France	15:10 15:20	Gene Regulation in Violation of the Inflammatory Response in Atherosclerosis Alexander Orekhov, Russia	15:40 16:00	Impact of lifestyle promotion, Nizwa Experience Zahir Al Anquodi, Oman
				14:30 14:50	Patient and citizen led organisations as the driver in the social context- The FH Europe Foundation case Magdalena Daccord, Switzerland
				14:50 15:10	Advocacy Case Study: Raising Cholesterol Awareness Brian Kennedy, USA
				15:10 15:30	Role of patient advocates in securing apheresis access in Lebanon Chyrel Lichaa, Lebanon
				15:30 15:40	Patient Testimonial San Fatih, Iraq
				15:40 15:50	Global Journey Of Person Living With FCS/Severe HTG Jill Praver, UK
				15:50 16:00	Circadian Disruption Of Cardiovascular Parameters Due To Rotating Night Shift Baby Anjum, India

15:20 15:30	High-resolution structure of LDL bound to the LDL receptor Alan T Remaley, USA
15:30 15:40	Global Disparities in Access to Lipid-Lowering and Family-Planning for HoFH Dirk Blom, South Africa
15:40 15:50	Lipid-lowering therapy: Are marine-based PCSK9 inhibitors an alternative to statins? Tengku Sifzizul Tengku Muhammad, Malaysia
15:50 16:00	PALISADE: A Phase 3 Study to Assess the Efficacy and Safety of Plozasiran in adults with Genetically or Clinically-Defined Familial Chylomicronemia Syndrome (FCS) at high risk of Acute Pancreatitis (AP) Gerald Watts, Australia

16:00 - 16:30 Coffee Break / Exhibition

16:30
17:30

Joint Session - European Atherosclerosis Society
Chairperson:
Kausik Ray, UK

INTERASPIRE: International survey on secondary prevention of cardiovascular disease across six WHO regions
Kornelia Kotseva, UK

INTERAPSIRE: Lipid Results
Kausik Ray, UK

International Atherosclerosis Society Chairperson:
Peter Libby, USA

INTERASPIRE: The global burden of hypertriglyceridemia
Peter Libby, USA

16:30
17:30

Joint Session - Oman Diabetes Association
Chairperson:
Noor Al Busaidi, Oman

Obesity and cardiovascular disease:
Hani Sabbour, United Arab Emirates

Lifestyle Medicine Weight Management:
Saleh Alrajih, Saudi Arabia

World Obesity Federation
Chairperson: John Wilding, UK

Emerging medical therapies for obesity with CVD:
John Wilding, UK

16:30
17:30

Joint Session - International Atherosclerosis Society
Chairperson:
Samia Mora, USA

Oman Society for Lipid and Atherosclerosis
Chairperson:
Khalid Al Rasadi, Oman

Gulf Center for Disease Prevention
Chairperson: Faiza Aljabry, Oman

M&E of NCD in the GCC countries:
Rasha Al Fawaz, Saudi Arabia

The future of GCC joint registries and NCD surveillance:
Bushra Alghamdi, Saudi Arabia

Translating data into knowledge:
Abdulaziz Alzayed, Saudi Arabia

16:30
17:30

Joint Session: Oman Society for Lipid and Atherosclerosis
Chairperson:
Manal Al Kindi, Oman

Cascade Screening for Dyslipidemia in Oman
Fahad Al Zadjali, Oman

Lipid Association of India
Chairperson:
S S Iyenger, India

Lipid Association of India 2023 update on cardiovascular risk assessment and lipid management in Indian patients:
Raman Puri, India

6 December 2024 - Program

Hall A - Matrah		Hall B - Salalah		Hall C - Nizwa		Hall D - Sur	
8:00 Onwards	Registration						
8:00 8:45	Meeting of the IAS Council of Constituent Societies						
9:00 10:30	Plenary Sessions - Combatting Atherosclerosis Chairpersons: Noor Al Busaidi, Oman Raul Santos, Brazil						
9:00 9:30	Exploring the Cardiorenal Axis Chiadi Ndumele, USA						
9:30 10:00	Effect of Emerging Anti-obesity and Anti-diabetic Agents on Atherosclerosis Ada Cuevas, Chile						
10:00 10:30	Recent trials in cardiometabolic medicine Paul Ridker, USA						
10:30 - 11:00 Coffee Break / Exhibition / Poster Viewing							
11:00 12:00	Parallel Session: Emerging Science in Cardiovascular Disease and Role of Inflammation, Stress, and Thrombosis Chairpersons: Jessia Peña, USA Amal Al Hashmi, Oman Peter Tontono, USA	11:00 12:00	Parallel Session: Familial Hypercholesterolemia: Worldwide Experience Chairpersons: Elsie Evans, UK Frederick Raal, South Africa Nizal Sarrafzadegan, Iran	11:00 12:00	Parallel Session: Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): Epidemiology, pathogenesis, and Treatment Chairpersons: Raul Santos, Brazil Jumana Saleh, Oman Ashna Nastar, Singapore	11:00 12:00	Parallel Session: Applying Artificial Intelligence and Omics Technologies in Atherosclerotic Cardiovascular Disease Chairpersons: Olga Demler, Switzerland Adhari AlZaabi, Oman Wael Almahmeed, UAE
11:00 11:20	Inflammatory markers and ASCVD in daily practice Michal Vrablik, Czech Republic	11:00 11:15	Implementation of Better Care for FH: an IAS Perspective Gerald Watts, Australia	11:00 11:20	The single and combined roles of PCSK7 and PCSK9 in MASLD Nabil Seidah, Canada	11:00 11:20	Digitalisation and AI in diabetes care, advantages, practice, challenges Peter Schwarz, Germany
11:20 11:30	Comparison of omega-3 fatty acids on plaque stability in mice Kristen Bubb, Australia	11:15 11:25	The Molecular Basis of Different Genetic Lipid Disorders in Lebanon Carine Ayoub, Lebanon	11:15 11:25	MAFLD and Subclinical Atherosclerosis Mustafa Al Hinai, Oman	11:20 11:35	Technology for lipoprotein partitioning: clinical relevance of small dense LDL Manfredi Rizzo, Italy
11:30 11:40	CD36-dependent metabolic rewiring drives dyslipidaemia induced platelet hyperactivity Khalid Naseem, UK	11:25 11:35	Homozygous Familial Hypercholesterolemia Evaluation and Survival in Saudi Arabia (HESSA) Naji Kholaf, Saudi Arabia	11:25 11:35	MASLD, Atherosclerosis & Diabetes: Trioka of cardiovascular disease Adnan Agha, UAE	11:35 11:45	Personalized AI-delivered Lifestyle intervention for Diabetes/Prediabetes in Primary care Niall Colwell, Ireland
11:40 11:50	Diroximel fumarate reduces atherosclerotic plaque size and instability Christina Bursill, Australia	11:35 11:45	Eleven years follow-up of 1324 young FH-individuals in Norway Gisle Langslet, Norway	11:35 11:50	MASLD in Oman and the GCC: Addressing a Growing Public Health Trend Said Al Busafi, Oman	11:45 11:55	Role of AI and Omics Technologies in Advancing Atherosclerosis Research and management Hasina Al Harthi, Oman
11:50 12:00	Can Antibiotics Inhibit the Growth of Abdominal Aortic Aneurysm? Meta-Analysis Mohamed Hamouda Elkasaby, Egypt	11:45 12:00	Contemporary Management of HoFH: Insights from the Real-World Italian Experience Marcello Arca, Italy	11:50 12:00	Anti-Endoglin monoclonal antibody effects on activation of hepatic fibrosis in vitro Petr Nachtigal, Czech Republic	11:55 12:10	SCAP as a Potential Therapeutic Target for Colorectal Cancer Aisha Al-Naamani, Oman

<p>12:00 12:45</p> <p>International Atherosclerosis Society Sponsored by Novo Nordisk Speakers: Session Title: Targeting Inflammation in Residual Atherosclerotic Risk</p> <p>Immunobiology of Atherosclerosis Peter Libby, USA</p> <p>Regulation of Inflammation in Atherosclerosis Christina Bursill, Australia</p> <p>Clinical Utility of Biomarkers for Inflammation Jessica Peña, USA</p>	<p>12:00 13:00</p> <p>Sponsored Symposium - Global Alliance for Patient Access Session Title: Addressing the Global Challenges Impacting Cholesterol Management</p> <p>Raul Santos, Brazil Brian Kennedy, USA Susan Hepworth, USA</p>	<p>12:00 12:25</p> <p>Sponsored Symposium - Amgen Session Title: Role of Evolocumab in Dyslipidemia Management of Established MI Patients: Raya Almazrouei</p>	
---	--	---	--

13:00 - 14:00 Coffee Break / Exhibition / Prayer

<p>14:00 15:30</p> <p>NLA Endo Award Lecture: Paul Ridker, USA Fruchart Award Lecture: Peter Tontonoz, USA</p>	<p>14:00 15:30</p> <p>Publish, Don't Perish (Journal Session) Chairpersons: John Chapman, France Ibrahim Al-Zakwani, Oman</p> <p>Speakers: Kerry-Anne Rye, Australia Jan Borén, Sweden Irene Fernández-Ruiz, Spain Gerald Watts, Australia Samir Al Adawi, Oman</p>		<p>14:00 15:00</p> <p>Joint Session - Diabetes India Chairperson: S R Arvind, India</p> <p>Diabetes Care in India Challenges and Solutions Banshi Saboo, India</p> <p>International Atherosclerosis Society Chairperson: Ada Cuevas, Chile</p> <p>A Holistic Framework for Dysglycemia: UAE Cardiometabolic Guidelines: Nada Ayedh Binhareez, UAE</p> <p>Oman Diabetes Association Chairperson: Ali Al Mamari, Oman</p> <p>Strategies for National Diabetes Care and Prevention: Noor Al Busaidi, Oman</p>
<p>15:30 16:30</p> <p>Joint Session - Oman Diabetes Association Chairperson: Noor Al Busaidi, Oman</p> <p>Weight Management for Diabetes and CVD John Wilding, UK</p> <p>International Diabetes Federation Chairperson: Peter Schwarz, Germany</p> <p>Digital Health application for diabetes management and prevention - the German experience: Peter Schwarz, Germany</p>	<p>15:00 16:00</p> <p>Joint Session - Oman Heart Association Chairperson: Adil Barakat Al Riyami, Oman</p> <p>A call for aggressive lipid management in the Middle East: Kadhim Suliman, Oman</p> <p>Gulf Heart Association Chairperson: Wael Mahmeed, UAE</p> <p>Lipid control in Gulf ACS patients: Results from large contemporary registry: Mohammed Zubaid, Kuwait</p> <p>World Heart Federation Chairperson: Nooshin Bazargani, UAE</p> <p>The cholesterol Road Map highlight from the international perspective: Raul Santos, Brazil</p>	<p>15:00 16:00</p> <p>Joint Session - International Atherosclerosis Society Chairperson: Marianne Abifadel, Lebanon</p> <p>How to make it happen in FH Gerald Watts, Australia</p> <p>IberoAmerican FH Network Chairperson: Rodrigo Alonso, Chile</p> <p>FH in iberoamerica: the challenge we have to face Rodrigo Alonso, Chile</p>	<p>15:00 16:00</p> <p>Joint Session - Oman Society of Lipid and Atherosclerosis Chairperson: Khamis Al Hashmi, Oman</p> <p>The Role of Non-Statins in patients with elevated Triglyceride Rich Lipoprotein and Atherosclerotic Cardiovascular Diseases Khalid Al Walli, Oman</p> <p>Korean Society of Lipid and Atherosclerosis Chairperson: Sung Hee Choi, South Korea</p> <p>The role of ezetimibe in reducing statin associated muscle symptoms in Korea: Soon Jun Hong, South Korea</p> <p>Role of non-statin agents in the management of MASLD: Yong-ho Lee, South Korea</p>

16:30 - 17:00 Closing Ceremony